Selected research
Industry Research
Female Contraception Drug Industry Research Report 2026
Market perspective
The global Female Contraception Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Female Contraception Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Female Contraception Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Female Contraception Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Female Contraception Drug include Teva Pharmaceutical Industries Ltd, Bayer AG, Viramal Ltd, Orbis Biosciences Inc, Mithra Pharmaceuticals SA, Hervana Ltd, Evofem Inc, Agile Therapeutics Inc and Addex Therapeutics Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Female Contraception Drug market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Female Contraception Drug Market by Company
Teva Pharmaceutical Industries Ltd
Bayer AG
Viramal Ltd
Orbis Biosciences Inc
Mithra Pharmaceuticals SA
Hervana Ltd
Evofem Inc
Agile Therapeutics Inc
Addex Therapeutics Ltd
Female Contraception Drug Segment by Type
AG-890
Drospirenone
BAY-1007626
Amphora
Others
Female Contraception Drug Segment by Application
Homecare
Hospital
Clinic
Female Contraception Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Female Contraception Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Female Contraception Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Female Contraception Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Female Contraception Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Female Contraception Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Female Contraception Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- AG-890
- Drospirenone
- BAY-1007626
- Amphora
- Others
Applications
- Homecare
- Hospital
- Clinic
Companies covered
- Teva Pharmaceutical Industries Ltd
- Bayer AG
- Viramal Ltd
- Orbis Biosciences Inc
- Mithra Pharmaceuticals SA
- Hervana Ltd
- Evofem Inc
- Agile Therapeutics Inc
- Addex Therapeutics Ltd
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Female Contraception Drug Market Size (2021-2032)
- 2.2.2 Global Female Contraception Drug Sales (2021-2032)
- 2.2.3 Global Female Contraception Drug Market Average Price (2021-2032)
- 2.3 Female Contraception Drug by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 AG-890
- 2.3.3 Drospirenone
- 2.3.4 BAY-1007626
- 2.3.5 Amphora
- 2.3.6 Others
- 2.4 Female Contraception Drug by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Homecare
- 2.4.3 Hospital
- 2.4.4 Clinic
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Female Contraception Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Female Contraception Drug Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Female Contraception Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Female Contraception Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Female Contraception Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Female Contraception Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Female Contraception Drug, Product Type & Application
- 3.8 Global Manufacturers of Female Contraception Drug, Established Date
- 3.9 Global Female Contraception Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Teva Pharmaceutical Industries Ltd
- 4.1.1 Teva Pharmaceutical Industries Ltd Company Information
- 4.1.2 Teva Pharmaceutical Industries Ltd Business Overview
- 4.1.3 Teva Pharmaceutical Industries Ltd Female Contraception Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Teva Pharmaceutical Industries Ltd Female Contraception Drug Product Portfolio
- 4.1.5 Teva Pharmaceutical Industries Ltd Recent Developments
- 4.2 Bayer AG
- 4.2.1 Bayer AG Company Information
- 4.2.2 Bayer AG Business Overview
- 4.2.3 Bayer AG Female Contraception Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Bayer AG Female Contraception Drug Product Portfolio
- 4.2.5 Bayer AG Recent Developments
- 4.3 Viramal Ltd
- 4.3.1 Viramal Ltd Company Information
- 4.3.2 Viramal Ltd Business Overview
- 4.3.3 Viramal Ltd Female Contraception Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Viramal Ltd Female Contraception Drug Product Portfolio
- 4.3.5 Viramal Ltd Recent Developments
- 4.4 Orbis Biosciences Inc
- 4.4.1 Orbis Biosciences Inc Company Information
- 4.4.2 Orbis Biosciences Inc Business Overview
- 4.4.3 Orbis Biosciences Inc Female Contraception Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Orbis Biosciences Inc Female Contraception Drug Product Portfolio
- 4.4.5 Orbis Biosciences Inc Recent Developments
- 4.5 Mithra Pharmaceuticals SA
- 4.5.1 Mithra Pharmaceuticals SA Company Information
- 4.5.2 Mithra Pharmaceuticals SA Business Overview
- 4.5.3 Mithra Pharmaceuticals SA Female Contraception Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Mithra Pharmaceuticals SA Female Contraception Drug Product Portfolio
- 4.5.5 Mithra Pharmaceuticals SA Recent Developments
- 4.6 Hervana Ltd
- 4.6.1 Hervana Ltd Company Information
- 4.6.2 Hervana Ltd Business Overview
- 4.6.3 Hervana Ltd Female Contraception Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Hervana Ltd Female Contraception Drug Product Portfolio
- 4.6.5 Hervana Ltd Recent Developments
- 4.7 Evofem Inc
- 4.7.1 Evofem Inc Company Information
- 4.7.2 Evofem Inc Business Overview
- 4.7.3 Evofem Inc Female Contraception Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Evofem Inc Female Contraception Drug Product Portfolio
- 4.7.5 Evofem Inc Recent Developments
- 4.8 Agile Therapeutics Inc
- 4.8.1 Agile Therapeutics Inc Company Information
- 4.8.2 Agile Therapeutics Inc Business Overview
- 4.8.3 Agile Therapeutics Inc Female Contraception Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Agile Therapeutics Inc Female Contraception Drug Product Portfolio
- 4.8.5 Agile Therapeutics Inc Recent Developments
- 4.9 Addex Therapeutics Ltd
- 4.9.1 Addex Therapeutics Ltd Company Information
- 4.9.2 Addex Therapeutics Ltd Business Overview
- 4.9.3 Addex Therapeutics Ltd Female Contraception Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Addex Therapeutics Ltd Female Contraception Drug Product Portfolio
- 4.9.5 Addex Therapeutics Ltd Recent Developments
5 Global Female Contraception Drug Market Scenario by Region
- 5.1 Global Female Contraception Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Female Contraception Drug Sales by Region: 2021-2032
- 5.2.1 Global Female Contraception Drug Sales by Region: 2021-2026
- 5.2.2 Global Female Contraception Drug Sales by Region: 2027-2032
- 5.3 Global Female Contraception Drug Revenue by Region: 2021-2032
- 5.3.1 Global Female Contraception Drug Revenue by Region: 2021-2026
- 5.3.2 Global Female Contraception Drug Revenue by Region: 2027-2032
- 5.4 North America Female Contraception Drug Market Facts & Figures by Country
- 5.4.1 North America Female Contraception Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Female Contraception Drug Sales by Country (2021-2032)
- 5.4.3 North America Female Contraception Drug Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Female Contraception Drug Market Facts & Figures by Country
- 5.5.1 Europe Female Contraception Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Female Contraception Drug Sales by Country (2021-2032)
- 5.5.3 Europe Female Contraception Drug Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Female Contraception Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Female Contraception Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Female Contraception Drug Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Female Contraception Drug Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Female Contraception Drug Market Facts & Figures by Country
- 5.7.1 South America Female Contraception Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Female Contraception Drug Sales by Country (2021-2032)
- 5.7.3 South America Female Contraception Drug Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Female Contraception Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Female Contraception Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Female Contraception Drug Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Female Contraception Drug Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Female Contraception Drug Sales by Type (2021-2032)
- 6.1.1 Global Female Contraception Drug Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Female Contraception Drug Sales Market Share by Type (2021-2032)
- 6.2 Global Female Contraception Drug Revenue by Type (2021-2032)
- 6.2.1 Global Female Contraception Drug Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Female Contraception Drug Revenue Market Share by Type (2021-2032)
- 6.3 Global Female Contraception Drug Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Female Contraception Drug Sales by Application (2021-2032)
- 7.1.1 Global Female Contraception Drug Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Female Contraception Drug Sales Market Share by Application (2021-2032)
- 7.2 Global Female Contraception Drug Revenue by Application (2021-2032)
- 7.2.1 Global Female Contraception Drug Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Female Contraception Drug Revenue Market Share by Application (2021-2032)
- 7.3 Global Female Contraception Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Female Contraception Drug Value Chain Analysis
- 8.1.1 Female Contraception Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Female Contraception Drug Production Mode & Process
- 8.2 Female Contraception Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Female Contraception Drug Distributors
- 8.2.3 Female Contraception Drug Customers
9 Global Female Contraception Drug Analyzing Market Dynamics
- 9.1 Female Contraception Drug Industry Trends
- 9.2 Female Contraception Drug Industry Drivers
- 9.3 Female Contraception Drug Industry Opportunities and Challenges
- 9.4 Female Contraception Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst